MA53126A - Agents de dégradation sélectifs du récepteur des oestrogènes - Google Patents
Agents de dégradation sélectifs du récepteur des oestrogènesInfo
- Publication number
- MA53126A MA53126A MA053126A MA53126A MA53126A MA 53126 A MA53126 A MA 53126A MA 053126 A MA053126 A MA 053126A MA 53126 A MA53126 A MA 53126A MA 53126 A MA53126 A MA 53126A
- Authority
- MA
- Morocco
- Prior art keywords
- estrogen receptor
- selective estrogen
- degradation agents
- receptor degradation
- agents
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697100P | 2018-07-12 | 2018-07-12 | |
| PCT/US2019/041342 WO2020014440A1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53126A true MA53126A (fr) | 2021-05-19 |
| MA53126B1 MA53126B1 (fr) | 2023-02-28 |
Family
ID=67470734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53124A MA53124B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
| MA53126A MA53126B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs du récepteur des oestrogènes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53124A MA53124B1 (fr) | 2018-07-12 | 2019-07-11 | Agents de dégradation sélectifs des récepteurs des oestrogènes |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10654866B2 (fr) |
| EP (2) | EP4155310A1 (fr) |
| JP (4) | JP6995241B2 (fr) |
| KR (3) | KR102550538B1 (fr) |
| CN (2) | CN112638916B (fr) |
| AR (1) | AR115694A1 (fr) |
| AU (2) | AU2019299947B2 (fr) |
| BR (2) | BR112020025654A2 (fr) |
| CA (1) | CA3105501C (fr) |
| CL (1) | CL2021000045A1 (fr) |
| CO (1) | CO2021000043A2 (fr) |
| CR (1) | CR20210007A (fr) |
| DK (1) | DK3820873T3 (fr) |
| EA (1) | EA202092975A1 (fr) |
| EC (1) | ECSP21001770A (fr) |
| ES (1) | ES2933980T3 (fr) |
| FI (1) | FI3820873T3 (fr) |
| HR (1) | HRP20230009T1 (fr) |
| HU (1) | HUE060963T2 (fr) |
| IL (3) | IL280065B (fr) |
| JO (1) | JOP20210005A1 (fr) |
| LT (1) | LT3820873T (fr) |
| MA (2) | MA53124B1 (fr) |
| MD (1) | MD3820873T2 (fr) |
| MX (2) | MX2021000375A (fr) |
| PE (1) | PE20210400A1 (fr) |
| PH (1) | PH12021550049A1 (fr) |
| PL (1) | PL3820873T3 (fr) |
| PT (1) | PT3820873T (fr) |
| RS (1) | RS63809B1 (fr) |
| SA (1) | SA521421008B1 (fr) |
| SG (1) | SG11202100148TA (fr) |
| SI (1) | SI3820873T1 (fr) |
| TW (1) | TWI702219B (fr) |
| UA (1) | UA127507C2 (fr) |
| WO (1) | WO2020014435A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310489A (en) | 2015-10-01 | 2024-03-01 | Olema Pharmaceuticals Inc | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment |
| PL3820874T3 (pl) * | 2018-07-12 | 2023-02-06 | Eli Lilly And Company | Selektywne środki degradujące receptor estrogenowy |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| CN114957114A (zh) * | 2021-02-26 | 2022-08-30 | 冷志 | 一种4-溴-3-氯-7-甲氧基喹啉的合成方法 |
| KR20230144571A (ko) | 2021-03-09 | 2023-10-16 | 일라이 릴리 앤드 캄파니 | Serd 투여 요법의 조합을 사용하여 암을 치료하는 방법 |
| TW202300492A (zh) * | 2021-03-16 | 2023-01-01 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| US11926634B2 (en) | 2022-02-01 | 2024-03-12 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
| WO2024083716A1 (fr) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinaisons d'un serd pour le traitement du cancer |
| WO2024097206A1 (fr) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Inhibiteurs chroménones allostériques de la phosphoinositide 3-kinase (pi3k) pour le traitement d'une maladie |
| WO2024100236A1 (fr) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Polythérapies pour le traitement du cancer |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004531562A (ja) * | 2001-05-22 | 2004-10-14 | イーライ・リリー・アンド・カンパニー | ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法 |
| US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| EP1497277A1 (fr) * | 2002-04-19 | 2005-01-19 | Signal Pharmaceuticals, Inc. | Composes benzopyranone, compositions contenant ces composes et methodes de traitement associees |
| US20090023917A1 (en) | 2004-01-22 | 2009-01-22 | Eli Lilly And Company | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms |
| US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| EP3010502B1 (fr) | 2013-06-19 | 2018-11-21 | Seragon Pharmaceuticals, Inc. | Modulateurs azétidine des récepteurs d' oestrogènes et leurs utilisations |
| CN107406424B (zh) * | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| JP6679147B2 (ja) * | 2014-12-18 | 2020-04-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用 |
| WO2018108954A1 (fr) | 2016-12-12 | 2018-06-21 | F. Hoffmann-La Roche Ag | Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol |
| PL3820874T3 (pl) * | 2018-07-12 | 2023-02-06 | Eli Lilly And Company | Selektywne środki degradujące receptor estrogenowy |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2019
- 2019-07-02 TW TW108123257A patent/TWI702219B/zh active
- 2019-07-03 AR ARP190101886A patent/AR115694A1/es unknown
- 2019-07-11 CA CA3105501A patent/CA3105501C/fr active Active
- 2019-07-11 MA MA53124A patent/MA53124B1/fr unknown
- 2019-07-11 MX MX2021000375A patent/MX2021000375A/es unknown
- 2019-07-11 KR KR1020217000466A patent/KR102550538B1/ko active IP Right Grant
- 2019-07-11 MD MDE20210462T patent/MD3820873T2/ro unknown
- 2019-07-11 EP EP22201995.2A patent/EP4155310A1/fr active Pending
- 2019-07-11 KR KR1020227044200A patent/KR102589886B1/ko active IP Right Grant
- 2019-07-11 RS RS20221142A patent/RS63809B1/sr unknown
- 2019-07-11 LT LTEPPCT/US2019/041334T patent/LT3820873T/lt unknown
- 2019-07-11 CN CN201980046849.3A patent/CN112638916B/zh active Active
- 2019-07-11 PT PT197459258T patent/PT3820873T/pt unknown
- 2019-07-11 SG SG11202100148TA patent/SG11202100148TA/en unknown
- 2019-07-11 ES ES19745925T patent/ES2933980T3/es active Active
- 2019-07-11 BR BR112020025654-4A patent/BR112020025654A2/pt unknown
- 2019-07-11 KR KR1020237034781A patent/KR20230148386A/ko not_active Application Discontinuation
- 2019-07-11 EA EA202092975A patent/EA202092975A1/ru unknown
- 2019-07-11 FI FIEP19745925.8T patent/FI3820873T3/fi active
- 2019-07-11 US US16/508,745 patent/US10654866B2/en active Active
- 2019-07-11 PE PE2020002017A patent/PE20210400A1/es unknown
- 2019-07-11 UA UAA202100102A patent/UA127507C2/uk unknown
- 2019-07-11 PL PL19745925.8T patent/PL3820873T3/pl unknown
- 2019-07-11 DK DK19745925.8T patent/DK3820873T3/da active
- 2019-07-11 CN CN202311312431.7A patent/CN117379428A/zh active Pending
- 2019-07-11 JP JP2021500536A patent/JP6995241B2/ja active Active
- 2019-07-11 CR CR20210007A patent/CR20210007A/es unknown
- 2019-07-11 BR BR122023025061-3A patent/BR122023025061A2/pt unknown
- 2019-07-11 SI SI201930406T patent/SI3820873T1/sl unknown
- 2019-07-11 MA MA53126A patent/MA53126B1/fr unknown
- 2019-07-11 WO PCT/US2019/041334 patent/WO2020014435A1/fr unknown
- 2019-07-11 AU AU2019299947A patent/AU2019299947B2/en active Active
- 2019-07-11 HU HUE19745925A patent/HUE060963T2/hu unknown
- 2019-07-11 JO JOP/2021/0005A patent/JOP20210005A1/ar unknown
- 2019-07-11 HR HRP20230009TT patent/HRP20230009T1/hr unknown
- 2019-07-11 EP EP19745925.8A patent/EP3820873B1/fr active Active
-
2020
- 2020-05-18 US US16/876,819 patent/US11117902B2/en active Active
-
2021
- 2021-01-06 CO CONC2021/0000043A patent/CO2021000043A2/es unknown
- 2021-01-07 CL CL2021000045A patent/CL2021000045A1/es unknown
- 2021-01-08 PH PH12021550049A patent/PH12021550049A1/en unknown
- 2021-01-10 IL IL280065A patent/IL280065B/en unknown
- 2021-01-11 MX MX2023006047A patent/MX2023006047A/es unknown
- 2021-01-12 SA SA521421008A patent/SA521421008B1/ar unknown
- 2021-01-12 EC ECSENADI20211770A patent/ECSP21001770A/es unknown
- 2021-09-02 US US17/465,066 patent/US11634426B2/en active Active
- 2021-12-14 JP JP2021202668A patent/JP7009672B1/ja active Active
-
2022
- 2022-01-12 JP JP2022003022A patent/JP7241211B2/ja active Active
- 2022-01-16 IL IL289871A patent/IL289871B2/en unknown
- 2022-06-08 AU AU2022203969A patent/AU2022203969B2/en active Active
- 2022-08-14 IL IL295598A patent/IL295598B2/en unknown
-
2023
- 2023-03-06 JP JP2023033486A patent/JP2023081954A/ja active Pending
- 2023-03-15 US US18/121,667 patent/US11993608B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53126A (fr) | Agents de dégradation sélectifs du récepteur des oestrogènes | |
| DK3820874T3 (da) | Selektive estrogenreceptornedbrydere | |
| DK3386500T3 (da) | Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer | |
| DE112020001082A5 (de) | Löschvorrichtung | |
| MA52555A (fr) | Modulateurs du récepteur des oestrogènes | |
| DK3746678T3 (da) | Fastspændingsindretning | |
| DK3412840T3 (da) | Toilet | |
| DE112019001011A5 (de) | Schaltvorrichtung | |
| ES1230351Y (es) | Dispositivo embellecedor de peldanos | |
| ES1230844Y (es) | Dispositivo de conmutación | |
| UA40063S (uk) | Лійка | |
| EP3816357C0 (fr) | Dispositif de toilettes | |
| DK3611373T3 (da) | Lynreceptorbeslag | |
| ES1227379Y (es) | Dispositivo de fijacion poliaxial | |
| DK3453804T3 (da) | Skylleindretning | |
| ES1256693Y (es) | Dispositivo antiposada | |
| DE112020003471A5 (de) | Sitzanordnung | |
| ES1246657Y (es) | Dispositivo de soporte de bicicletas | |
| MA53666A (fr) | Purification de stérol | |
| ES1232390Y (es) | Dispositivo anti-grafitis | |
| ES1216609Y (es) | Dispositivo de protección para columpios | |
| ES1203686Y (es) | Aparato de sujecion de premarcos | |
| ES1217885Y (es) | Inodoro antisalpicaduras | |
| ES1211889Y (es) | Dispositivo sonoro de accionamiento manual | |
| TH1501002663A (th) | อุปกรณ์ฝารองนั่งชักโครกชำระล้าง (Water Flushing Toilet Seat Device) |